0HFQ Stock Overview
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
AnaptysBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.39 |
| 52 Week High | US$41.25 |
| 52 Week Low | US$12.59 |
| Beta | -0.017 |
| 1 Month Change | -39.54% |
| 3 Month Change | -56.85% |
| 1 Year Change | n/a |
| 3 Year Change | -59.07% |
| 5 Year Change | 33.62% |
| Change since IPO | -86.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HFQ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 9.8% | 3.3% | 1.3% |
| 1Y | n/a | -23.4% | 4.3% |
Return vs Industry: Insufficient data to determine how 0HFQ performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0HFQ performed against the UK Market.
Price Volatility
| 0HFQ volatility | |
|---|---|
| 0HFQ Average Weekly Movement | 16.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HFQ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0HFQ's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 117 | Dan Faga | www.anaptysbio.com |
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
AnaptysBio, Inc. Fundamentals Summary
| 0HFQ fundamental statistics | |
|---|---|
| Market cap | US$406.53m |
| Earnings (TTM) | -US$165.66m |
| Revenue (TTM) | US$57.17m |
7.1x
P/S Ratio-2.5x
P/E RatioIs 0HFQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HFQ income statement (TTM) | |
|---|---|
| Revenue | US$57.17m |
| Cost of Revenue | US$154.78m |
| Gross Profit | -US$97.60m |
| Other Expenses | US$68.05m |
| Earnings | -US$165.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.44 |
| Gross Margin | -170.72% |
| Net Profit Margin | -289.75% |
| Debt/Equity Ratio | 415.5% |
How did 0HFQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 21:25 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AnaptysBio, Inc. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neena Bitritto-Garg | Baird |
| Eliana Merle | Cantor Fitzgerald & Co. |
| Alethia Young | Credit Suisse |